CASTLE BIOSCIENCES, INC. Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price
CASTLE BIOSCIENCES, INC. (CSTL) reported Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price of $6.79 per share for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-07-30.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice · last filed 2026-07-30
- CASTLE BIOSCIENCES, INC. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for the quarter ending 2026-03-31 was $11.30, a 293.73% increase year-over-year.
- CASTLE BIOSCIENCES, INC. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for the quarter ending 2025-03-31 was $2.87, a 15.59% decline year-over-year.
- CASTLE BIOSCIENCES, INC. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for the quarter ending 2024-03-31 was $3.40, a 9.68% increase year-over-year.
- CASTLE BIOSCIENCES, INC. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for the quarter ending 2023-03-31 was $3.10, a 51.71% decline year-over-year.
- CASTLE BIOSCIENCES, INC. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for fiscal 2025 was $20.34, a 36.97% increase from fiscal 2024.
- CASTLE BIOSCIENCES, INC. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for fiscal 2024 was $14.85, a 293.90% increase from fiscal 2023.
- CASTLE BIOSCIENCES, INC. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for fiscal 2023 was $3.77, a 32.56% decline from fiscal 2022.
- CASTLE BIOSCIENCES, INC. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for fiscal 2022 was $5.59, a 44.82% decline from fiscal 2021.
| Period end | Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price 3 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price 6 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price 9 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price 12 month |
|---|---|---|---|---|
| 2026-06-30 | $6.79 10-Q · filed 2026-07-30 | |||
| 2026-03-31 | $11.30 10-Q · filed 2026-05-06 | |||
| 2025-12-31 | $20.34 10-K · filed 2026-02-26 | |||
| 2025-09-30 | $5.44 10-Q · filed 2025-11-03 | |||
| 2025-06-30 | $2.16 10-Q · filed 2025-08-04 | |||
| 2025-03-31 | $2.87 10-Q · filed 2025-05-05 | |||
| 2024-12-31 | $14.85 10-K · filed 2026-02-26 | |||
| 2024-09-30 | $14.78 10-Q · filed 2024-11-04 | |||
| 2024-06-30 | $3.51 10-Q · filed 2024-08-05 | |||
| 2024-03-31 | $3.40 10-Q · filed 2024-05-02 | |||
| 2023-12-31 | $3.77 10-K · filed 2026-02-26 | |||
| 2023-09-30 | $3.96 10-Q · filed 2023-11-02 | |||
| 2023-06-30 | $4.01 10-Q · filed 2023-08-02 | |||
| 2023-03-31 | $3.10 10-Q · filed 2023-05-03 | |||
| 2022-12-31 | $5.59 10-K · filed 2025-02-27 | |||
| 2022-09-30 | $5.83 10-Q · filed 2022-11-02 | |||
| 2022-06-30 | $5.15 10-Q · filed 2022-08-08 | |||
| 2022-03-31 | $6.42 10-Q · filed 2022-05-09 | |||
| 2021-12-31 | $10.13 10-K · filed 2023-02-28 | |||
| 2021-09-30 | $10.58 10-Q · filed 2021-11-08 | |||
| 2021-06-30 | $8.22 10-Q · filed 2021-08-09 | |||
| 2021-03-31 | $5.67 10-Q · filed 2021-05-10 | |||
| 2020-12-31 | $3.53 10-K · filed 2022-02-28 | |||
| 2020-09-30 | $2.08 10-Q · filed 2020-11-09 | |||
| 2020-06-30 | $1.97 10-Q · filed 2020-08-10 | |||
| 2020-03-31 | $2.16 10-Q · filed 2020-05-11 | |||
| 2019-12-31 | $1.70 10-K · filed 2021-03-11 | |||
| 2019-09-30 | $1.70 10-Q · filed 2019-11-12 | |||
| 2018-12-31 | $1.91 10-K · filed 2020-03-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lumexa Imaging Holdings, Inc. (LMRI) | United States | $0.951B | |
| Fulgent Genetics, Inc. (FLGT) | United States | $0.593B | -6.70 |
| Personalis, Inc. (PSNL) | United States | $1.769B | -13.30 |
| BIODESIX INC (BDSX) | United States | $0.312B | |
| Fortrea Holdings Inc. (FTRE) | United States | $1.903B | -19.43 |
| EXAGEN INC. (XGN) | United States | $0.212B | -5.95 |
| Freenome, Inc. (FRNM) | United States | $0.143B | |
| SERA PROGNOSTICS, INC. (SERA) | United States | $0.062B | -5.75 |
| AMERICAN SHARED HOSPITAL SERVICES (AMS) | United States | $0.010B | -5.64 |
| Advanced Biomed Inc. (ADVB) | $0.009B |